Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
An epic month of biotech stock performance ends with a significant sell off.
If history repeats, investor optimism for NewLink's phase III study is misplaced.
InterMune's Esbriet improved lung function and delayed disease progression in pivotal phase III study.
An investor short Endocyte explains his negative view on the upcoming European approval decision in ovarian cancer and why the lung cancer study is likely to fail.
The No. 1 stock on this list has more than half its float short.
Sales of the prescription fish-oil are so low that generic drug makers may simply pass the product by.
The decision to change out the primary and secondary endpoints was made as part of discussions with the FDA, a Vertex spokesman said.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biotech investing goes mainstream.